New antihemorrhagic agents: a novel antifibrinolytic strategy

-
Hemorrhage is a leading cause of death and cost associated with blood transfusion.
-
There is a need for the improvement of current treatments of bleeding associated with surgery, trauma, intracerebral hemorrhage (ICH) or other tissue damages.
-
A novel target involved in fibrinolysis has been identified.
-
Proprietary novel compounds to prevent major bleeding have been developed:
-
Small molecule entity (SME).
-
Efficacy: 30,000 times more effective than the currently available therapies.
-
Safety: No thrombus formation and no impact on coagulation.
-
-
Primary Indication: prophylaxis and acute treatment of bleeding in cardiac surgery.
![]() |
Programas de investigación Programas de investigación en los que puede participar con el CIMA Acuerdos y programas de investigación del CIMA [PDF] |

Su objetivo es optimizar con el máximo nivel de calidad e innovación el abanico de diagnósticos genéticos e inmunofenotípicos que se desarrollan en diferentes laboratorios de la Universidad de Navarra. |
Contacta con nosotros |
Contacto:
Centro de Investigación Médica Aplicada (CIMA) Avenida Pío XII, 55 31008 Pamplona España +34 948 194 700 cima@unav.es |